Estrogen Receptor Sites in the Developing Central Nervous System and Their Relationships to Catecholamine Systems

Author(s):  
W. E. Stumpf ◽  
M. Sar ◽  
I. Reisert ◽  
Ch. Pilgrim
1987 ◽  
Vol 10 (6) ◽  
pp. 422-435 ◽  
Author(s):  
M. Schlumpf ◽  
A. Bruinink ◽  
W. Lichtensteiger ◽  
R. Cortés ◽  
J.M. Palacios ◽  
...  

2004 ◽  
Vol 75 (5) ◽  
pp. 603-613 ◽  
Author(s):  
Dina N. Arvanitis ◽  
Huimin Wang ◽  
Richard D. Bagshaw ◽  
John W. Callahan ◽  
Joan M. Boggs

2008 ◽  
Vol 7 (6) ◽  
pp. 7290.2008.00027 ◽  
Author(s):  
Alessia Stell ◽  
Silvia Belcredito ◽  
Paolo Ciana ◽  
Adriana Maggi

Estrogen receptors have long been known to be expressed in several brain areas in addition to those directly involved in the control of reproductive functions. Investigations in humans and in animal models suggest a strong influence of estrogens on limbic and motor functions, yet the complexity and heterogeneity of neural tissue have limited our approaches to the full understanding of estrogen activity in the central nervous system. The aim of this study was to examine the transcriptional activity of estrogen receptors in the brain of male and female mice. Exploiting the ERE-Luc reporter mouse, we set up a novel, bioluminescence-based technique to study brain estrogen receptor transcriptional activity. Here we show, for the first time, that estrogen receptors are similarly active in male and female brains and that the estrous cycle affects estrogen receptor activity in regions of the central nervous system not known to be associated with reproductive functions. Because of its reproducibility and sensitivity, this novel bioluminescence application stands as a candidate as an innovative methodology for the study and development of drugs targeting brain estrogen receptors.


1985 ◽  
Vol 107 (2) ◽  
pp. 247-250 ◽  
Author(s):  
J. C. Reubi

ABSTRACT Long-term treatment for more than 3 months with a central nervous system (CNS)-active drug, the opioid agonist bremazocine, at a dose of 1 mg/kg per day elicited an 80% inhibition of the volume of the subcutaneously transplanted rat prostate adenocarcinoma Dunning R3327H. Whereas, under this therapy, prostate tumour and prostatic weights were decreased, testes and pituitary weights remained normal. Bremazocine inhibited not only the growth of freshly transplanted tumours but also that of well-grown Dunning prostate carcinomas since, after 41 days of treatment, such tumours showed a volume inhibition of 52%. In these experiments bremazocine decreased LH and testosterone plasma levels significantly. Bremazocine, therefore, probably acts mainly through suprapituitary CNS-opiate receptor sites, which indirectly, rather than locally, mediate LH inhibition. Indeed, no specific receptors for bremazocine could be found in the Dunning tumour, which makes a local action of bremazocine in this tissue unlikely. The efficient tumour growth inhibition through the supra-pituitary action of bremazocine makes such opiate drugs, which lack respiratory and side effects due to improper use, of potential interest for treatment of prostatic tumours. J. Endocr. (1985) 107, 247–250


Sign in / Sign up

Export Citation Format

Share Document